Organon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) P/E ratio
As of 6 November 2026, Organon & Co. (OGN) trades at a P/E ratio of 17.3×. Over the past ten years it has ranged from 2.8× (May 2025) to 17.4× (September 2026); the current reading is higher than 98% of that period. That is below the Drug Manufacturers General industry median of 26.5× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 10.0× | 123.60% |
| FY2024 | 4.5× | 21.71% |
| FY2023 | 3.7× | (53.07%) |
| FY2022 | 7.8× | 36.48% |
| FY2021 | 5.7× | 25.89% |
| FY2020 | 4.5× | 0.00% |
| FY2019 | 4.5× | 0.00% |
| FY2018 | 4.5× | 0.00% |
| FY2017 | 4.5× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 17.1× | (0.08%) |
| Jun 2026 | 17.1× | 168.96% |
| Mar 2026 | 6.4× | (36.01%) |
| Dec 2025 | 10.0× | 79.96% |
| 23 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AMRN Amarin Corporation PLC compare | n/m |
| NVO Novo Nordisk A/S compare | 10.1× |
| BMY Bristol Myers Squibb Company compare | 13.7× |
| GSK GSK PLC Sponsored ADR compare | 16.7× |
| OGN Organon & Co. | 17.3× |
| GRFS Grifols, S.A. compare | 18.2× |
| SNY Sanofi compare | 23.3× |
| PFE Pfizer Inc. compare | 41.3× |
| BIIB Biogen Inc. compare | 105× |
| Drug Manufacturers General industry median | 26.5× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on OGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement